+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Organ-On-A-Chip Innovations Fueling Drug Screening Applications

  • Report

  • 70 Pages
  • June 2018
  • Region: Global
  • Frost & Sullivan
  • ID: 4591055

Novel Organ-chip Platforms Likely to Transform the Drug Screening Process in the Pharmaceutical Industry

Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight into the possible in vivo effects of drugs in the human body. The flexibility of Organ-on-a-chip is such that the innovation is not just human-relevant per se but can mimic a wide variety of human functions such as breathing, heartbeats, peristalsis, menstruation, neuronal communication.

Animal models and in vitro assays have served as the gold standard for pre-clinical research and study for a long time now. But for all the benefits, animal models and in vitro assays have seen poor results in human translation and prediction due to unsatisfactory human relevance. Organ-on-a-chip innovations are currently making themselves relevant by offering better data for human translation and prediction through their high degree of human-relevant systems.

The US are currently the frontrunners in the Organ-on-a-chip technology followed closely by Netherlands, United Kingdom, and Germany. The countries have been capitalized on the need for a better study model in drug screening application to pioneer the development of Organ-on-a-chip innovations which has seen relative success in the pharmaceutical industry as evidenced by the adoption of Organ-chip technology by major pharmaceutical companies such as Roche, AstraZeneca among many others.

Table of Contents

1. Executive Summary
1.1 Research Scope - Application of Organ-on-a-chip Technology in Drug Screening Process
1.2 Research Methodology - Core Value
1.3 Key Findings: Organ-on-a-chip Technology
2. Technology Snapshot
2.1 A Brief Overview of Organ-on-a-chip Functioning
2.2 Key Factors Empowering Organ-on-a-chip Technologies for Drug Screening Processes
2.3 Current Trends in the Organ-on-a-chip platform
3. Organ-on-a-chip Platforms
3.1 Heart-on-a-chip Platform
3.2 Liver-on-a-chip Platform
3.2.1 High Throughput Capability of Liver-on-a-chip Platforms Integral to Large-Scale Drug Screening Applications
3.2.2 Flow Systems Adopted in Liver-on-a-chip Platforms that Facilitate Stability
3.3 Lung-on-a-chip Platform
3.3.1 Lung-on-a-chip: Platform Overview, Application, Disadvantages, and Features
3.4 Kidney-on-a-chip Platform
3.4.1 Kidney-on-a-chip: Features, Platform Design, Applications, and Challenges
3.5 Gut-on-a-chip/Intestine-on-a-chip Platform
3.5.1 Intestine- and Gut-on-a-chip Serve as Enhanced Study Models
3.5.2 Intestine- and Gut-on-a-chip: The Applications and the Challenges
3.6 Nerve-on-a-chip Platform
3.6.1 Evaluation of Neurotoxicity with the Nerve-on-a-chip platform
3.7 Muscle-on-a-chip Platform
3.7.1 Muscle-on-Chip Platform to Determine Long-term rug effects on Muscle Loss and Toxicity
3.7.2 Muscle-on-a-chipPhysiology, Features and Application Areas
3.8 Brain-on-a-chip Platform
3.8.1 Emulation of Human-Blood-Brain Barrier
3.9 Multi-Organ Chip Platforms
3.10 Human-on-a-chip Platform
4. Drivers and Challenges of Organ-Chip Technology
4.1 Drivers and Challenges Impact Chart of Organ-Chip Technology
4.2 Organ-on-a-chip Technology
4.3 Stem ell henotypes key to unlocking vast otential of Organ-chip Systems
5. Major Organ-on-a-chip Companies
5.1 A Well-defined and Robust Nerve-on-a-chip Platform
5.2 CN Bio- UK’s Organ-chip Technology Pioneer
5.3 Emulate propelling Drug Screening and Development through their
5.4 Hesperos facilitates superior Serum-free Media and Pumpless Organ-Chip Systems
5.5 Liver-on-a-chip platforms with High Biological Fidelity
5.6 Scaffold-free Human Relevant Liver-on-a-Chip Systems
5.7 Validated Research-ready Organ-chip Systems
5.8 Organ-Chips that facilitate High Throughput Screening
5.9 Precise Flow-controlled ParVivo Organ-Chip Systems
5.10 Replicating In Vivo Cardiac Biology on an n Vitro Chip Platform
5.11 TissUse pioneering Human-on-a-Chip platform
6. Intellectual Property Landscape of Organ-on-a-chip Technology
6.1. Patent Research Scope and Concepts
6.2 Top 20 Patent Holders in the Organ-on-a-chip Platform
6.3 Patent Office-wise Distribution of Organ-on-a-chip Patent Portfolio, 2008-2018*
6.4 Year-wise Publication Distribution of Organ-on-a-chip Patent Portfolio, 2008-2017
7. Funding Landscape of Organ-on-a-chip Technology
7.1 Funding Strength of Organ-Chip Technology- Global View
7.2 Government Funding for Organ-on-a-chip Development
7.3 Venture Capitalist-based Investment Funding in the OOC Market
7.4.Animal Free Research involved in Funding of Organ-on-a-chip Technology Development
8. Growth Opportunities
8.1 Growth Opportunity 1: Personalized Medicine
8.2 Growth Opportunity 2: Animal Model Replacement
8.3 Growth Opportunity 3: Identification of Biomarkers
8.4 Determinants of Organ-on-a-chip Platform’s Impact on Drug Screening Process
9. Appendix
9.1 Key Contacts
9.2 Legal Disclaimer